al. reported a murine blocking antibody against AGR2 that can reduce growth and metastasis of pancreatic cancers and suppress AGR2 client protein C4.4a, hence there are possibilities to use therapeutic agents to abrogate extracellular metastatic receptor activities [70]. Here, AGR2 is linked to pancreatic neoplasm.